Accolade vs Quantum Health

Side-by-side comparison of model-estimated upside.

Accolade

-64%

est. 2Y upside i

Healthcare

Rank

#3746

Sector

Healthcare Technology

Est. Liquidity

~3Y

Data Quality

Data: High

The equity opportunity in Transcarent (post-Accolade acquisition) is risky, with an expected upside of 7% over a two-year horizon.

Last updated: March 10, 2026

Quantum Health

-22%

est. 2Y upside i

Healthcare

Rank

#2153

Sector

Healthcare Technology / Navigation

Est. Liquidity

~2Y

Data Quality

Data: Medium

Quantum Health is a healthcare navigation powerhouse: $1B+ ARR, 25-year data moat, 8M members, IPO candidate.

Last updated: March 21, 2026

Note: These companies have different risk levels. Accolade (Higher Risk) and Quantum Health (Moderate Risk). A higher expected upside in a higher-risk company comes with greater uncertainty. Compare within the same risk tier for more meaningful evaluation.

Upside Comparison

Expected Upside

Accolade

-64%

Quantum Health

-22%

Disclaimer: These rankings are AI-generated estimates and do not constitute financial or career advice. Always conduct your own due diligence.